ATTD 2025 showcased 36 startups revolutionizing diabetes care with innovations like non-invasive monitoring, AI diagnostics, and real-time health tools. Awarded grants highlighted ATTD’s commitment to advancing personalized, tech-driven solutions that empower patients and transform global diabetes management.

The 17th ATTD Conference (Amsterdam, 19–22 March 2025) showcased major innovations in diabetes care. The 15-day Dexcom G7 CGM proved accurate and user-friendly. The RADIANT trial showed Omnipod® 5 significantly improved glucose control over injections in type 1 diabetes. In type 2 diabetes, the 2IQP Study highlighted benefits of AID systems. Teplizumab also showed potential to enhance glycaemic stability in newly diagnosed type 1 diabetes, reinforcing the role of technology and immunotherapy in advancing diabetes management.

Women & Diabetes takes centre stage in this interview with Zeina Abou Rizk, Founder of DiaLeb. Zeina explores the unique challenges women face in diabetes care, the power of community and advocacy, and how DiaLeb’s annual panel fosters global awareness, education, and meaningful change through lived experiences and expert insights.

Dr Linda Siminerio, a leading expert in diabetes education and healthcare delivery, shares insights from her distinguished career. Inspired by her father’s type 1 diabetes diagnosis, she has dedicated her work to improving patient education and care models. She emphasizes the importance of a team-based approach and staying ahead of technological advancements. With AI and machine learning already influencing diabetes management, she urges healthcare providers to adapt and engage with these innovations. Through her contributions, Dr Siminerio continues to shape the future of diabetes care, ensuring that patients receive the education and support they need.

Dr Svenja Nölting shares how her international experiences and dedicated mentors shaped her career in neuroendocrine oncology, discusses the profound impact of hormones on the body, and highlights the future of precision medicine in tailoring treatments for endocrine disorders.

Eneboparatide is an investigational parathyroid hormone receptor 1 (PTH1R) agonist, designed to bind with high affinity to a specific conformation of PTH1R, which is expressed in the kidneys and bone. The goal of treatment is to restore function by producing sustained and stable levels of calcium in the blood and by restoring calcium reabsorption by the kidney.2,3 Eneboparatide has been developed to have a short half-life in order to preserve bone health.

Watch four leading experts discuss how AI is transforming the clinical management of paediatric endocrine disorders including growth hormone disorders.

New research, published in the Nature journal, Communications Medicine has identified rare genetic variants that may contribute to the increased prevalence of type 2 diabetes (T2D) in multiple generations of Asian Indian families.1 The findings could provide new insights into ...

"From Adolescence to Menopause: Modern Management of Endometriosis and Uterine Diseases" will be the central theme of the 11th Annual SEUD Congress, taking place April 24–26, 2025, in Prague, Czech Republic. This premier event will unite global experts in gynecology, endometriosis, and uterine disorders to explore the latest advancements in research, diagnosis, and treatment. With an innovative scientific program, engaging discussions, and interactive sessions, SEUD 2025 promises to be an essential gathering for professionals committed to women’s health.